Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies.

Christopher T RitchlinJon T GilesPhilip S HelliwellJuan J Gomez-ReinoPhilip S HelliwellPamela YoungCunshan WangJoseph WuAna Belén RomeroJohn WoolcottLori Stockert

Published in: ACR open rheumatology (2020)

Regardless of baseline MetS status, tofacitinib showed greater efficacy versus placebo in patients with active PsA. The tofacitinib safety profile appeared similar in patients with versus without MetS.

Keyphrases

rheumatoid arthritis
metabolic syndrome
ulcerative colitis
prostate cancer
insulin resistance
radical prostatectomy
cardiovascular disease
skeletal muscle
placebo controlled